Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3E4MT | ISIN: US78397T2024 | Ticker-Symbol:
NASDAQ
04.11.24
20:34 Uhr
3,990 US-Dollar
+0,210
+5,56 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SAB BIOTHERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
SAB BIOTHERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur SAB BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.09.SAB Biotherapeutics, Inc.: SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference1
12.09.Oppenheimer keeps Outperform rating on SAB Biotherapeutics shares1
09.09.SAB Biotherapeutics, Inc. - 8-K, Current Report1
04.09.SAB Biotherapeutics, Inc.: SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting1
12.08.SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
09.08.SAB Biotherapeutics GAAP EPS of -$0.791
08.08.SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates126FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)...
► Artikel lesen
08.08.SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report1
05.08.SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes461MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing...
► Artikel lesen
31.07.SAB Biotherapeutics names Lucy To as CFO1
31.07.SAB Biotherapeutics, Inc. - 8-K, Current Report1
31.07.SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer103MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is...
► Artikel lesen
27.06.SAB Biotherapeutics, Inc. - 8-K, Current Report1
20.06.SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook1
20.06.SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO114New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)...
► Artikel lesen
18.06.SAB Biotherapeutics, Inc.: SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions1
30.05.SAB Biotherapeutics announces departure of CFO1
30.05.SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer181MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
► Artikel lesen
21.05.SAB Biotherapeutics GAAP EPS of -$0.43 beats by $0.601
21.05.SAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 Diabetes1
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1